Background: Early life adversity has been identified as a potentially causal factor in the development of mental disorders. Little is known, however, about the association between various types of early life adversities and social cognitive function in adults with major psychiatric disorders, such as schizophrenia, borderline personality disorder, bipolar disorder and major depressive disorder. We conducted a systematic review aimed at elucidating possible underlying cognitive mechanisms that may form the pathway between early life adversities and social cognitive dysfunction. Methods: Relevant studies were identified via electronic and manual searches of the literature, and included peer reviewed English language articles published up to May 2017. Quality of individual articles was assessed using the quality evaluation scale. Results: A total of 15 studies were included in the systematic review with the quality assessment scores ranging from 2 to 5 (out of 6). The majority of the studies demonstrated that various types of early life adversities, specifically physical neglect, emotional and sexual abuse and insecure attachment, are significantly associated with social cognitive function. Discussion: Presented in the context of an attachment model, we conclude that childhood adversity results in poor internal working models, selective attention towards emotional stimuli and greater difficulties with emotional self-regulation. The importance of these findings for development of interventions which diminish the adverse effects of childhood maltreatment on social cognition is discussed.
S7. NEOSENSITIZATION TO MULTIPLE DRUGS FOLLOWING DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS SYNDROME (DRESS)
Background: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome is associated with severe skin eruptions, fever, hematological abnormalities, and multi-organ involvement. Although aromatic anticonvulsant drugs have been frequently associated with the manifestation of DRESS syndrome, its induction following treatment with nonaromatic anticonvulsants, such as valproate, has rarely been reported. Moreover, there are limited data regarding the development of neosensitization related to chemically unrelated drugs following an episode of DRESS syndrome. Methods: Here, a case of neosensitization to multiple drugs is described. The present case report describes a female patient who experienced neosensitization to amoxicillin, olanzapine, and quetiapine following the manifestation of DRESS syndrome induced by valproate.
Results:
A 50-year-old woman with a 15-year history of schizophrenia was being treated with lithium (1200 mg) and quetiapine (600 mg) about 1 month, but due to high lithium serum concentrations, the lithium was changed to valproate (600 mg). Seven days later, the patient developed a whole-body skin rash, facial edema, and hyperthermia. Laboratory tests revealed an abnormal white cell count (25.2 × 103 /μL with 6% eosinophils) and aspartate transaminase (AST) and alanine transaminase (ALT) concentrations of 2729 IU/L and 2749IU/L, respectively. At that time, the patient had no any other medical history including drug allergy. A diagnosis of DRESS syndrome due to valproate treatment was established by a consulting dermatologist. As a result, all medicines were discontinued because of severe hepatitis, and intravenous methylprednisolone (60 mg per day) was administered for 1 week. The skin rash, fever, and liver dysfunction progressively disappeared. After discharge, the patient was treated with quetiapine (200 mg). However, she became lost to follow up after 6 months. Approximately 3 years later, the patient was admitted to a local hospital for psychotic symptoms aggravation because she was not taken antipsychotics for 3 years. She treated with lithium (900 mg), sulpiride (600 mg), risperidone (2 mg), and quetiapine (100 mg) for 2 weeks. Additionally, the patient initiated treatment with amoxicillin for acute tonsillitis. On the first day of amoxicillin intake, she developed fever, diffuse erythematous macules on her trunk, and facial edema, and she was transferred to a general hospital via the emergency department. To control her psychotic symptoms she is prescribed olanzapine, haloperidol and quetiapine step by step but all these medications develop fever, skin rash and abnormal AST/ALT. Finally she was given amisulpiride which had not been previously prescribed. Within 2 months, the patient's psychotic symptoms had gradually decreased and ultimately remitted. Discussion: To our knowledge, this is the first case report of neosensitization to multiple drugs after valproate-induced DRESS syndrome. A thorough search of Pubmed was performed to identify similar cases, which confirmed that no cases of hypersensitivity to amoxicillin or neosensitization to multiple drugs after a valproate-related DRESS episode have been reported. Furthermore, only two studies have reported possible neosensitization to amoxicillin following DRESS episodes induced by carbamazepine, and only one case reported neosensitization to amoxicillin following a DRESS episode induced by allopurinol. 
S8. RELATIONSHIP BETWEEN ALLOSTATIC LOAD AND POOR FUNCTIONAL CAPACITY IN YOUTH AT ULTRA-HIGH RISK FOR PSYCHOSIS

Orygen, The National Centre of Excellence in Youth Mental Health
Background: Current pathophysiological models of psychotic disorders suggest that stress contributes to the aetiology and trajectory of the disorder. Allostatic load (AL), a multisystem index of immune, neuroendocrine and metabolic dysregulation, is thought to represent the cumulative biological impact of stress. Two recent studies suggest that AL is elevated in patients with first-episode psychosis and related to psychotic symptoms and poor social and occupational functioning. Here, we investigate the relationship between AL and clinical outcomes in individuals at ultra-high risk for psychosis. Methods: AL was measured in a sub-group of participants of the NEURAPRO study, a multicentre randomized-controlled trial of omega-3 polyunsaturated fatty acids versus placebo in people aged 13 -40 at UHR for psychosis. A total of 106 participants who underwent additional biomarker analysis were included in the present study. Biomarkers for the AL index were selected based on (1) representation of several physiological systems including the cardiovascular, neuroendocrine, immune, and metabolic systems, (2) use in previous AL research, and (3) associations with disease risk. We adopted a scaled AL algorithm whereby each marker proportionally contributes to the overall AL index. Clinical outcomes were assessed 3 and 12 months after study intake using the Social and Occupational Functioning Assessment Scale (SOFAS), the Brief Psychiatric Rating Scale (BPRS), the Scale for the Assessment of Negative Symptoms (SANS), the Montgomery-Asberg Depression Rating Scale (MADRS) and the Young Mania Rating Scale (YMRS). We hypothesised that AL would be (1) associated with higher symptoms scores and reduced functioning at baseline and (2) related to more severe symptoms and reduced functioning at the 3 and 12 month assessments. These hypotheses were tested by calculating Pearson correlation coefficients and by using linear regression modelling, respectively.
Results: No significant correlations of AL with any of the psychometric scales are observed at study intake. AL at baseline was associated with lower SOFAS scores at 3 months (B=-1.436, p=0.042) but not at 12 months (B=-1.096, p=0.297). No prospective associations of AL were found with any of the other psychometric measures (all p>0.05). Discussion: Our data support the notion that multisystem dysregulation, indexed as AL, may be a potential predictor of early treatment response and warrants further investigation. These observations are consistent with recent research demonstrating elevated AL in patients with psychotic disorders that is related to reduced functioning. Background: Numerous previous studies have found increased power in low frequencies in resting EEG data in subjects with a diagnosis of schizophrenia (Scz). Low frequency power in δ is usually localised to frontal channels, whereas increases in θ power can be more widespread (Boutros et al., 2008) . Given the low spatial resolution of EEG data, we used a spatial filter (the surface Laplacian) to investigate whether differences in resting EEG frequency band power in Scz are truly distributed throughout the cortex, or whether they localise to more focal areas. Methods: 64 channel EEG data were recorded for 5 minutes in both eyes closed and eyes open conditions in 103 medicated Scz (M=71, F=32, mean(std) age=40(14.3) yrs) and 104 controls (M=64, F=30, mean(std) age=40(13.8) yrs). The data were epoched and epochs with artefacts were detected by their amplitude, variance or kurtosis and removed. The power spectral density at each channel was computed using Welch's method, and the surface Laplacian (using the spherical spline method of Perrin et al. (1987 Perrin et al. ( , 1989 ) was applied to reduce volume conduction effects and improve topographical localization. Power was analysed separately for five frequency bands: δ (2-4 Hz), θ (4-8 Hz), α (8-12 Hz), β (15-30 Hz) and γ (30-50 Hz). Permutation testing (20 runs of 1000 group label permutations) was performed with correction for multiple comparisons based on clusters of channels of significantly different (p<0.05 uncorrected) power. Results: Scz and controls showed group differences in θ power (mean(std) over all channels, eyes open condition: Scz=5.7(10)x104 μVmm-2 and controls=3.2(5.9)x104 μVmm-2, t test, t(181) = 2.0, p = 0.047; and at trend level significance in the eyes closed condition: Scz=6.0(9.6)x104 μVmm-2 and controls=3.8(6.2)x104 μVmm-2, t test, t(181) = 1.8, p = 0.067), but no group differences in the other four frequency bands (all p >0.05). Scz had greater θ power in both eyes open and eyes closed conditions using clusterbased permutation tests (both p<0.05). The median cluster sizes (25% quantile, 75% quantile) with elevated θ power in Scz were of 53 (51, 55) channels in the eyes open and 50.5 (48, 51.5) in the eyes closed condition. Discussion: These initial results support previous findings of widespread increased θ band power in Scz (e.g. Narayanan et al., 2014). These θ differences appear to be manifest in the majority of the cortex, rather than being localised to one particular area. Background: Several lines of evidence support a role for astroglial pathology in schizophrenia. 1H-MRS does not specifically differentiate between brain cell types; nevertheless, given that myo-inositol (mIns) is particularly abundant in astroglia rather than neuron and microglial cells, it can be considered an astroglial marker. mIns levels in the brain can decrease after brain injury with an efflux of mIns from astrocytes occurring as an osmoregulatory response. Many small sized studies have reported on mIns concentration in schizophrenia, but to date these have not been pooled to estimate a collective effect size. Examining the state of mIns deficit is a critical step to delineate the role of astroglial cells in schizophrenia. We conducted a meta-analysis to investigate the aberrations in myo-inositol levels in the ACC of patients with schizophrenia and measured using magnetic resonance spectroscopy (MRS Results: Contrary to our expectations, in SCZ, there were no significant differences in ACC mIns in patients compared to HC (RFX=0.359, p= 0.057; 95% CI, -0.728 to 0.011; heterogeneity p = 0.0004). In the SCZ group, the mean effect size (Cohen's d) was d= 0.39, indicating a medium sized difference. There were several methodological issues in the reported studies. Notably, most studies reported on mIns spectrum only when seeking differences in other metabolites; voxel placements were not standardized across the published studies; majority of patients were medicated, in various stages of illness. There was no statistical evidence for a publication bias (p=0.8).
S9. RESTING EEG CHANGES IN SCHIZOPHRENIA
S10. ASTROGLIAL PATHOLOGY IN SCHIZOPHRENIA: A META-ANALYSIS OF MRS STUDIES OF ANTERIOR CINGULATE MYOINOSITOL
Discussion: There is a medium effect-size, albeit statistically insignificant, reduction in the concentration of mIns in the anterior cingulate cortex in patients with schizophrenia. Given that mIns is the most readily accessible cortical marker in vivo for astroglial activity, it may be feasible to use MRS to stratify patients with astroglial abnormality from those without such an abnormality in schizophrenia.
S11. BRAIN ABNORMALITIES ASSOCIATED WITH DISEASE-SPECIFIC AND GENETIC RISK FACTORS FOR SCHIZOPHRENIA
Vina Goghari* ,1
University of Toronto
Background: Schizophrenia is a severe disorder affecting approximately 1% of the population. The disorder is associated with symptoms such as false perceptions and beliefs and disturbances in affect and language production. In 2004 the total direct healthcare and non-healthcare cost in Canada was estimated at $2 billion, with an additional productivity loss estimated at $5 billion. Methods: I will present a program of research into disease-specific and genetic risk factors associated with structural and functional brain abnormalities, including morphology (amount of grey matter), structural connectivity (amount of white matter integrity), and brain functioning (amount of brain activity) in individuals with schizophrenia, their family members, and community controls using magnetic resonance imaging. As healthy
